Already a member? Sign in
Category: Prescription Drugs
Most Popular Types: Mobic, Apo-Meloxicam, Movalis (Show all)
Generic Name: Meloxicam
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of osteoarthritis and rheumatoid arthritis.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Pain | 152 | 37 |
|
|
|
|
|
| Fibromyalgia | 136 | 37 |
|
|
|
|
|
| Inflammation | 84 | 18 |
|
|
|
|
|
| Other | 34 | 7 |
|
|
|
||
| Pain, Inflamation, muscle spasms | 33 | 14 |
|
|
|
|
|
| Arthritis pain | 29 | 10 |
|
|
|
|
See all 504 patients currently taking Meloxicam
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Meloxicam
| Acid reflux | 10 | |
|---|---|---|
| Dry mouth (xerostomia) | 6 | |
| Dry nose | 5 | |
| Nasal sores | 5 | |
| Stomach pain | 5 | |
| Weakness in arms | 5 | |
| See all 41 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Meloxicam. See all 17 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 43 | ||
| Doctor's advice | 33 | ||
| Side effects too severe | 32 | ||
| Other | 21 | ||
| Course of treatment ended | 11 | ||
| Personal research | 5 | ||
| Change in health plan coverage | 5 | ||
| Not indicated | 5 | ||
| Expense | 4 |
Adherence
Taking treatment as prescribed
Adherence of Meloxicam
Always |
109 | 76% |
|
|---|---|---|---|
Usually |
17 | 12% |
|
Sometimes |
11 | 8% |
|
Never |
7 | 5% |
|
Burden
Difficulty being on treatment
Burden of Meloxicam
Very |
9 | 6% |
|
|---|---|---|---|
Somewhat |
4 | 3% |
|
A little |
18 | 13% |
|
Not at all |
113 | 78% |
|
Cost
Paid out of pocket
Cost of Meloxicam
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
1 | 1% |
|
$25-49 |
9 | 10% |
|
< $25 |
78 | 89% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 12, 2012.